Soluble Urokinase-Type Plasminogen Activator Receptor as a Diagnostic and Prognostic Marker for Neonatal Sepsis
Heba Ibrahim Abdallah;
Abstract
N
eonatal infections annually claim lives of 1.4 million neonates worldwide. Identification and treatment of newborns with infection are weak in many developing countries. The urokinase plasminogen activator receptor (uPAR) is expressed on different cell types including neutrophils, lymphocytes, monocytes, macrophages, certain cancer cells and vascular endothelial cells. Recently, suPAR has been suggested as a novel prognostic marker to identify high-risk patients, and may be useful for the clinical management of serious infectious diseases. Therefore, this study assessed suPAR levels as a potential early diagnostic and prognostic marker for neonatal sepsis.
A total of 105 full term neonates was enrolled; 70 neonates with clinical and laboratory signs of sepsis (34 males and 36 females with a male to female ratio of 1:1) and 35 healthy controls 19 males and 16 females with a male to female ratio of 1.2:1). Complete blood count, high sensitivity C-reactive protein (hs-CRP) and Tollner sepsis score including clinical and laboratory indicators were assessed. The diagnosis was verified thereafter by blood culture. According to the results of blood cultures, the studied septic neonates were classified into 2 groups: the culture-proven septic group and culture-negative septic one. suPAR levels were measured by ELISA on initial sepsis evaluation and at 48 hours after antibiotic therapy. For ethical reasons, cord blood samples were collected from control neonates and only samples from neonates that proved to be healthy by clinical examination and laboratory analysis were further analyzed for suPAR.
eonatal infections annually claim lives of 1.4 million neonates worldwide. Identification and treatment of newborns with infection are weak in many developing countries. The urokinase plasminogen activator receptor (uPAR) is expressed on different cell types including neutrophils, lymphocytes, monocytes, macrophages, certain cancer cells and vascular endothelial cells. Recently, suPAR has been suggested as a novel prognostic marker to identify high-risk patients, and may be useful for the clinical management of serious infectious diseases. Therefore, this study assessed suPAR levels as a potential early diagnostic and prognostic marker for neonatal sepsis.
A total of 105 full term neonates was enrolled; 70 neonates with clinical and laboratory signs of sepsis (34 males and 36 females with a male to female ratio of 1:1) and 35 healthy controls 19 males and 16 females with a male to female ratio of 1.2:1). Complete blood count, high sensitivity C-reactive protein (hs-CRP) and Tollner sepsis score including clinical and laboratory indicators were assessed. The diagnosis was verified thereafter by blood culture. According to the results of blood cultures, the studied septic neonates were classified into 2 groups: the culture-proven septic group and culture-negative septic one. suPAR levels were measured by ELISA on initial sepsis evaluation and at 48 hours after antibiotic therapy. For ethical reasons, cord blood samples were collected from control neonates and only samples from neonates that proved to be healthy by clinical examination and laboratory analysis were further analyzed for suPAR.
Other data
| Title | Soluble Urokinase-Type Plasminogen Activator Receptor as a Diagnostic and Prognostic Marker for Neonatal Sepsis | Other Titles | مستويات مستقبل اليوروكيناز الذائب المنشط للبلازمينوجين فى الاطفال حديثى الولاده المصابين بتسمم فى الدم كمؤشر للتشخيص ودلاله لمآل المرض | Authors | Heba Ibrahim Abdallah | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.